<code id='B9D6D98E44'></code><style id='B9D6D98E44'></style>
    • <acronym id='B9D6D98E44'></acronym>
      <center id='B9D6D98E44'><center id='B9D6D98E44'><tfoot id='B9D6D98E44'></tfoot></center><abbr id='B9D6D98E44'><dir id='B9D6D98E44'><tfoot id='B9D6D98E44'></tfoot><noframes id='B9D6D98E44'>

    • <optgroup id='B9D6D98E44'><strike id='B9D6D98E44'><sup id='B9D6D98E44'></sup></strike><code id='B9D6D98E44'></code></optgroup>
        1. <b id='B9D6D98E44'><label id='B9D6D98E44'><select id='B9D6D98E44'><dt id='B9D6D98E44'><span id='B9D6D98E44'></span></dt></select></label></b><u id='B9D6D98E44'></u>
          <i id='B9D6D98E44'><strike id='B9D6D98E44'><tt id='B9D6D98E44'><pre id='B9D6D98E44'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:focus    Page View:666
          Scientist walks up a strand of DNA -- First Opinion coverage from STAT
          Adobe

          Eli Lilly said Tuesday that it will pay $200 million to gene-editing firm Beam Therapeutics for Beam’s stake in Verve Therapeutics, another gene-editing company focused on treatments for heart disease.

          The deal, which also includes future milestone payments, is evidence that despite the pressure on biotechnology stocks there is still interest in very early cutting-edge technologies among big pharmaceutical players. It also provides Beam, which announced on Oct. 19 that it would cut 100 jobs, or 20% of its workforce, to save cash, a large infusion of money.

          advertisement

          “This is like a true win-win-win deal, which is rare in this business, but it’s really, really exciting to see,” said John Evans, Beam’s CEO, in an interview with STAT.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Anavex keeps shifting the goalposts in its clinical trials
          Anavex keeps shifting the goalposts in its clinical trials

          MollyFerguson/STATAnavexLifeSciencesisinatoughspot.Theserialdissemblerofclinicaltrialresultsmightbef

          read more
          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more

          How to use technology to prevent future drug shortages

          TherehasbeenapersistentshortageoftheADHDdrugAdderall.JennyKane/APMyfirstexposuretopharmaceuticalshor